Pfizer RSV vaccine candidate Phase 3 trial will focus on older adults

Pfizer has announced the third phase of its RSV vaccine candidate clinical trial for older adults. The company is calling the trial’s third phase ‘RENOIR,’ noting that it involves giving its RSVpreF vaccine candidate to adults ages 60 and older. The company anticipates enrolling around 30,000 participants for Phase 3 RENOIR in order to study the vaccine’s efficacy and safety. …